Sevoflurane preserved LV function after CPB with less evidence of myocardial damage in the first 36 h postoperatively. These data suggest a cardioprotective effect of sevoflurane during coronary artery surgery.
Background-Fractional P<0.001). At 3 years, major adverse cardiovascular events were not different between the angiography-guided and FFR-guided groups (12% versus 11%; hazard ratio, 1.030; 95% confidence interval, 0.627-1.692; P=0.908). However, the FFR-guided group compared with the angiography-guided group presented a significantly lower rate of angina (Canadian Cardiovascular Society class II-IV, 31% versus 47%; P<0.001). Conclusions-FFR-guided coronary artery bypass graft surgery was associated with a lower number of graft anastomoses and a lower rate of on-pump surgery compared with angiography-guided coronary artery bypass graft surgery. This did not result in a higher event rate during up to 36 months of follow-up and was associated with a lower rate of angina. Patients were divided into 2 groups: the angiography-guided group and the FFR-guided group. The angiography-guided group consisted of patients in whom no FFR was measured at the time of the preoperative coronary angiography and CABG was indicated solely on the basis of the angiographic severity of the coronary stenosis. The FFR-guided group consisted of patients in whom at least 1 intermediate stenosis was measured by FFR and grafted in the presence of FFR ≤0.80 or deferred with FFR >0.80. Coronary Angiography and FFR MeasurementCoronary angiography was performed by a standard percutaneous femoral or radial approach with 6F or 7F diagnostic or guiding catheters. After the administration of 200 to 300 µg intracoronary isosorbide dinitrate, the angiogram was repeated in the projection allowing the best possible visualization of the stenosis. Experienced operators not involved in the analysis of the data assessed stenosis severity. Multivessel disease was defined as the presence of stenosis in ≥2 major coronary arteries.Performance of FFR measurement was left to the operator's discretion. FFR was measured as previously described.11,12 Briefly, a pressuremonitoring guidewire (Certus PressureWire; St. Jude Medical Inc, St. Paul, MN) was advanced distal to the coronary artery stenosis. After the administration of intracoronary isosorbide dinitrate (200 μg), hyperemia was obtained with either intravenous infusion (140 μg·kg) or an intracoronary bolus of adenosine (70-100 μg). An FFR value ≤0.80 indicated an ischemia-producing coronary stenosis. Coronary Artery Bypass SurgeryThe type of surgery, namely on-pump or off-pump, and the number and type of grafts were left to the surgeon's discretion. Study End PointsPrimary end point of the study was the rate of major adverse cardiac events, defined as overall death, myocardial infarction, and target vessel revascularization occurring during up to 3 years of clinical followup. Secondary end points were all the individual end points included in major adverse cardiovascular events plus the number of graft anastomoses and symptoms at the last clinical follow-up available. Myocardial infarction was defined as previously described.13,14 Target vessel revascularization was defined as any percutaneous or surgical rev...
Aims:The aim of this study was to assess prospectively the clinical benefits of fractional flow reserve (FFR) in guiding coronary artery bypass grafting (CABG).Methods and results: GRAFFITI is a single-blinded, prospective, multicentre, randomised controlled trial of FFR-guided versus angiography-guided CABG. We enrolled patients undergoing coronary angiography, having a significantly diseased left anterior descending artery or left main stem and at least one more major coronary artery with intermediate stenosis, assessed by FFR. Surgical strategy was defined based on angiography, blinded to FFR values prior to randomisation. After randomisation, patients were operated on either following the angiography-based strategy (angiography-guided group) or according to FFR, i.e., with an FFR ≤0.80 as cut-off for grafting (FFR-guided group). The primary endpoint was graft patency at 12 months. Between March 2012 and December 2016, 172 patients were randomised either to the angiography-guided group (84 patients) or to the FFR-guided group (88 patients). The patients had a median of three [3; 4] lesions; diameter stenosis was 65% (50%; 80%), FFR was 0.72 (0.50; 0.82). Compared to the angiography-guided group, the FFR-guided group received fewer anastomoses (3 [3; 3] vs 2 [2; 3], respectively; p=0.004). One-year angiographic follow-up showed no difference in overall graft patency (126 [80%] vs 113 [81%], respectively; p=0.885). One-year clinical follow-up, available in 98% of patients, showed no difference in the composite of death, myocardial infarction, target vessel revascularisation and stroke.Conclusions: FFR guidance of CABG has no impact on one-year graft patency, but it is associated with a simplified surgical procedure. ClinicalTrials.gov Identifier: NCT01810224
Sevoflurane and desflurane but not propofol preserved left ventricular function after CPB in high-risk coronary surgery patients with less evidence of myocardial damage postoperatively.
FFR-guided CABG is associated with a significant reduction in the rate of overall death or myocardial infarction at 6-year follow-up as compared with angiography-guided CABG.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.